Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
Pilot Toxicity
 

Initial toxicology study performed in rats

 

No untoward effects were seen at doses up to

1.8 mg/kg/day i.p.